RACCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Research Alliance Corp III
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$10.23+0.07 (+0.69%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Research Alliance Corp III
Pharmaceutical Preparations, SIC 2834
Research Alliance Corp III is listed on Nasdaq under the ticker RACC, in the SEC industry Pharmaceutical Preparations. It is incorporated in E9 and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- Research Alliance Corp III
- Headquarters
- New York, NY
- Address
- 600 Fifth Avenue, 23rd Floor 10020
- Phone
- (617) 778-2500
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- RACC
- Exchange
- Nasdaq
- IPO date
- May 20, 2026
- Shares outstanding
- 9M, Aug 10, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2118032
- CUSIP
- G75226103
- ISIN
- USG752261036
- EIN
- 98-1918931
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew Hammond | Chief Executive Officer, Director | 275,000 |
| Henry William Stusnick | COO and CBO | – |
| Francis Sherman Adams | Chief Financial Officer | – |
| Alliance Holdings III LLC /Cayman Research | Director | 275,000 |
| Michael F. MacLean | Director | – |
| Timothy J. Miller | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 24, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 20, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| May 18, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |